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Abstract
Background: Good biomarkers for early detection of cancer lead to better prognosis. However, harvesting tumor tissue is
invasive and cannot be routinely performed. Global DNA methylation of peripheral blood leukocyte DNA was evaluated as a
biomarker for cancer risk.
Methods: We performed a meta-analysis to estimate overall cancer risk according to global DNA hypomethylation levels
among studies with various cancer types and analytical methods used to measure DNA methylation. Studies were
systemically searched via PubMed with no language limitation up to July 2011. Summary estimates were calculated using a
fixed effects model.
Results: The subgroup analyses by experimental methods to determine DNA methylation level were performed due to
heterogeneity within the selected studies (p,0.001, I
2: 80%). Heterogeneity was not found in the subgroup of %5-mC
(p=0.393, I
2: 0%) and LINE-1 used same target sequence (p=0.097, I
2: 49%), whereas considerable variance remained in
LINE-1 (p,0.001, I
2: 80%) and bladder cancer studies (p=0.016, I
2: 76%). These results suggest that experimental methods
used to quantify global DNA methylation levels are important factors in the association study between hypomethylation
levels and cancer risk. Overall, cancer risks of the group with the lowest DNA methylation levels were significantly higher
compared to the group with the highest methylation levels [OR (95% CI): 1.48 (1.28–1.70)].
Conclusions: Global DNA hypomethylation in peripheral blood leukocytes may be a suitable biomarker for cancer risk.
However, the association between global DNA methylation and cancer risk may be different based on experimental
methods, and region of DNA targeted for measuring global hypomethylation levels as well as the cancer type. Therefore, it
is important to select a precise and accurate surrogate marker for global DNA methylation levels in the association studies
between global DNA methylation levels in peripheral leukocyte and cancer risk.
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Introduction
Epigenetic processes are important in development and cell
differentiation, and can be altered by environment, diet, and aging
[1,2]. DNA methylation, which is a major epigenetic mechanism,
is involved in various biological processes including cancer [3–6].
DNA hypomethylation is an early event in human carcinogenesis
[7–9] and is associated with genetic instability in cancer cells
[10,11]. Methylation levels of DNA are maintained by DNA
methyltransferases (DNMTs). Dnmt3a and Dnmt3b are respon-
sible for de novo DNA methylation [12–14]. Thus inactivation of
DNMTs causes global hypomethylation of the genome or
hypomethylation of specific families of repeated sequences [14–
16]. However, mechanisms of DNA hypomethylation are not fully
understood. There are several mechanisms accounting for DNA
demethylation. Direct removal of the methyl group by methyl
CpG binding domain protein 2 (MBD2) has been reported [17],
although this result has not been confirmed by other authors
[18,19]. GADD45A (growth arrest and DNA-damage-inducible,
alpha) is associated with repair-mediated DNA demethylation
[20]. However, the work of Jin et al. [21] does not confirm this
association. DNA repair enzymes may demethylate DNA [22],
and direct evidence of base excision repair (BER) mediated DNA
demethylation has been proposed [23]. Brother of the regulator of
imprinted sites (BORIS) expression is associated with demethyl-
ation [24]. Woloszynska-Read et al. [25] has suggested that the
ratio of BORIS/CCCTC-binding factor (CTCF) expression is
related to DNA demethylation. Because direct removal of the
methyl group from the 59 position of the cytosine is unfavorable,
studies suggesting natural mechanisms of DNA demethylation
have been inconsistent.
The CG sequences of the promoter region are normally
unmethylated to allow gene expression, whereas mammalian DNA
repeats are highly methylated in somatic tissues [12,26]. DNA
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causes repression of TSGs. Hypomethylation of unique or
repeated DNA sequences may affect chromatin structure and
genomic instability, lead to transcription activation, and increase
expression of cancer-promoting genes [26]. Both DNA hypo-
methylation and hypermethylation have been observed in human
cancer, but hypomethylation of DNA, especially in repetitive
elements, are more frequently associated with cancer, resulting in
net losses of 5-methylcytosine (5-mC) [26].
The association between global hypomethylation of tumor
DNA and cancer risk has been demonstrated in various human
tumors [27–30]. In addition, global hypomethylation of DNA in
various cancer and adjacent normal tissues has been detected
[31,32]. Therefore, many investigators have studied DNA
methylation as a biomarker for cancer screening. Early detection
of cancer results in better prognosis. However, harvesting tumor
tissue is invasive and cannot be routinely performed. Therefore,
the association between cancer risk and global DNA hypo-
methylation levels in blood leukocytes has been investigated.
We performed a meta-analysis to estimate overall cancer risk
according to global DNA hypomethylation levels among studies
with various cancer types and analytical methods used to measure
DNA methylation.
Methods
Study selection
We systemically searched for studies via the electronic databases
using PubMed with the terms ‘‘cancer risk and (methylation or
hypomethylation) and (blood or leukocyte)’’ with no language
limitation up to July 2011. A manual search with a reference list of
selected journals was performed. However, no new articles
meeting the inclusion criteria were identified. The inclusion/
exclusion criteria were as follows: (1) the original article with case-
control or cohort designs; (2) peripheral blood leukocytes were
used to measure global DNA methylation levels; (3) patients who
were newly diagnosed with cancer in case-control studies, and
blood was collected in participants who were free of cancers at
baseline in cohort studies; (4) the studies with gene-specific DNA
methylation were excluded; and (5) the study reported 95%
confidence intervals (CI) with adjusted odds ratios (OR) or relative
risks (RR) for cancer risk in subjects with the lowest level of global
DNA methylation compared to that in patients with the highest
level of global DNA methylation. If the reference cell contained
the lowest level of global DNA methylation, inversed OR and 95%
CI was used.
Data collection
Searched studies were independently reviewed by two investi-
gators (H.D.W and J.K.). Studies with eligible data for meta-
analysis contained information on authors, publication year,
experimental methods to measure global DNA methylation levels,
cancer sites and types, country where the study was performed,
study period, number of cases and controls, categories of global
DNA methylation levels, adjusted OR/RR and 95% CI, p-values
for trends, and confounding variables were considered. Adjusted
OR/RR and 95% CI were selected to exclude confounding effects
and to include the studies that did not report the number of cases
and controls for each category.
Statistical analysis
All statistical analyses were performed using the STATA
software package (version 10, College Station, TX). Log point
effect estimates and the corresponding standard errors were
calculated using covariate-adjusted point effect estimates and 95%
CI from selected studies and weighted by the inverse variance to
calculate summary estimates [33]. The heterogeneity test across
studies was measured using the Q-test based on the x
2 statistic,
considering significant statistical heterogeneity as p,0.05, and the
I
2 test according to Higgins et al. [34]. Subgroup analyses were
conducted by experimental methods to measure global DNA
methylation levels or based on cancer type due to between-study
heterogeneity. A fixed effect model was used in the meta-analysis
because a random effect model is less conservative than a fixed
effect model by giving more weight to small sample studies, which
are more likely to have publication bias, especially when small
numbers of the studies were combined [35,36].
Results
A total of 258 studies were excluded in the first pass based on
titles and abstracts among 285 searched articles. The remaining 27
studies were further reviewed. Eighteen studies that did not meet
inclusion criteria were excluded for the following reasons: 12
studies did not measure global DNA methylation levels; two
studies did not report the cancer risk according to categories of
global DNA methylation levels; 3 studies were review articles; and
1 study did not have control subjects. Eleven studies comprising
ten case-control studies and 1 cohort study were finally selected
(Table 1) [37–47]. We found 2 studies that were newly published
during the review process [45,46]. Because only a limited number
of studies met the criteria for our meta-analysis, we decided to
include these 2 additional studies (Figure 1). Because Pufulete et al.
[37] have reported both the risks of colorectal cancer and
colorectal adenoma, twelve cases were used for meta-analysis.
Three bladder cancer, two colorectal adenomas, one colorectal
cancer, one breast cancer, two gastric cancer, one head and neck
squamous cell carcinoma (HNSCC), one renal cell cancer, and
one overall cancer case were included. Zhu et al. [47] have
reported the risks of all cancer as well as each type of cancers
categorized into two and four group of global DNA hypomethyla-
tion levels. However, the data from all cancer risk with two
categories were selected due to the small number of cancer
incidence. Lim et al. [39] and Liao et al. [45] have reported OR
and 95% CI in people of the highest tertile of genomic methylation
compared to those in the lowest tertile of genomic methylation.
Therefore, we used the inversed OR and 95% CI to calculate the
pooled estimate. Egger’s test for publication bias showed non-
significant results (p=0.483).
Figure 2 shows the meta-analysis of the selected studies. Global
DNA hypomethylation was associated with increased cancer risk
(OR: 1.48, 95% CI: 1.28–1.70, p,0.001). However, between-
study heterogeneity was significantly high (p,0.001, I
2: 83%).
Therefore, we conducted meta-regression using experimental
methods used to determine global DNA methylation levels [methyl
acceptance capacity of DNA, percentage of 5-methylcytosine (%5-
mC) vs. long interspersed nucleotide element 1 (LINE-1)], cancer
sites (colorectal, stomach, others vs. bladder), and sex (male, total
vs. female). Experimental methods were significantly different
from each other (%5-mC vs. LINE-1: p=0.011) when sex and
experimental methods were included in the meta-regression
model. However, no significant differences were observed when
cancer site was further included. Four population-based studies
were identified, including 1 nested case-control study; all the
studies showed homogeneous summary estimates (OR [95%
CI]=1.36 [1.12–1.64]; heterogeneity test: p=0.159, I
2=42%).
However, the experimental methods of these 4 studies, which
involved LINE-1 analysis and hospital-based investigations, still
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not show any differences with regard to inclusion of the study
design in the analysis. Therefore, we did not include the study
design in our analysis. Subgroup analyses were performed by
experimental methods (%5-mC, LINE-1) and studies of bladder
cancer to further explore the variance among studies (Figure 3).
Heterogeneity among studies was not detected on %5-mC method
(p=0.393, I
2=0%), but considerable variance was found in the
subgroup analysis of LINE-1 method (p,0.001, I
2: 80%) and
bladder cancer (p=0.016, I
2: 76%). The group with the lowest
global DNA methylation levels had significantly higher cancer
risks compared to the group with the highest global DNA
methylation levels in %5-mC and LINE-1 studies [OR (95% CI):
2.93 (2.14–4.01) and 1.20 (1.03–1.41), respectively]. In the LINE-1
subgroup, with the exception of the study by Hsiung et al. [38] and
Liao et al. [45] which used different region of DNA target
sequence from other studies, I
2 statistics were 49% (p=0.097) and
global DNA hypomethylation levels were significantly associated
with increased cancer risk [OR (95% CI): 1.36 (1.12–1.65)].
Discussion
Eleven studies were used in the present study to estimate overall
results. These studies have tested whether global DNA methylation
level in peripheral blood DNA is a good marker to detect cancer.
Global DNA hypomethylation of blood leukocytes was associated
with increased cancer risk. However, the association varied
according to the experimental methods used and region of DNA
targeted for measuring global hypomethylation levels as well as the
cancer type.
Three experimental methods were identified to measure global
DNA methylation levels in the present meta-analysis: Three
studies used %5-mC; seven studies used LINE-1 with pyrose-
quencing (6 studies) and a modified version of the combined
bisulfite restriction analysis of the LINE retrotransposable element
1(LRE1) sequence (1 study); one study analyzed the methyl
acceptance capacity of DNA using [3H-methyl] S-adenosylmethi-
onine. Subgroup analysis in % 5-mC method was homogeneous.
However, LINE-1 method and bladder cancer, which was the only
cancer type that was analyzed in more than 3 studies, remained
significantly heterogeneous. Many analytical methods have been
developed to determine DNA methylation levels [48–51]. Methyl
acceptance assay is based on the capacity of radio-labeled methyl
incorporation into DNA, thus high methyl group incorporation
indicates lower levels of DNA methylation. However, high day-to-
day variation and inaccurate DNA concentration due to the
difficulty of mixing genomic DNA solution homogenously have
been observed [52]. The direct measurement of percentages of 5-
methylcytosine was used in many epidemiological studies to
estimate global DNA methylation contents using reversed-phase
high-performance liquid chromatography (HPLC), liquid chro-
matography (LC)-mass spectrometry, or high-performance capil-
lary electrophoresis (HPCE). These methods are highly quantita-
tive and reproducible, but they are not suitable for epidemiological
studies with large sample size and high amount of DNA are
required to yield reliable results. Introduction of sodium bisulfite
conversion of genomic DNA has revolutionized the analytical
methods in methylation analysis [13]. In addition, pyrosequencing
which is a high-throughput and accurate method is currently
available [51]. Repetitive sequences comprise large portions of the
human genome and are CpG-rich [53,54]. Repetitive genomic
regions such as LINE-1 and Alu are usually methylated in somatic
tissues [55]. Therefore, pyrosequencing with bisulfite-treated DNA
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PLoS ONE | www.plosone.org 4 April 2012 | Volume 7 | Issue 4 | e34615to measure repetitive element methylation has been used as
surrogate markers for global DNA hypomethylation.
However, in the study of Choi et al. [41], global DNA meth-
ylation levels were measured with %5-mC and LINE-1 in a pilot
study. However, both methods did not correlate with each other,
and the LINE-1 methylation level showed no significant dif-
ferences between cases and controls. No statistical significant
correlation between %5-mC and LINE-1 might be due to the low
sample size in a pilot study, but correlation coefficient was still very
small (r=20.204). Therefore, LINE-1 may not be appropriate to
serve as a sensitive surrogate marker for global DNA methylation.
In addition, Nelson et al. [56] reported that methylation levels
with LINE-1 method can be varied depending on the target CpG
sequence and across samples. The CpG sequence frequently used
Figure 1. Flow diagram of study selection.
doi:10.1371/journal.pone.0034615.g001
Figure 2. Forest plot of the association between cancer risks and global DNA hypomethylation in peripheral blood leukocytes.
Colorectal A: Colorectal Adenoma, Methyl: Methyl acceptance assay, LINE-1: Long interspersed nuclear elements, and %5-mC: Percentages of 5-
methylcytosine. F: Fixed effects model, R: random effects model. The horizontal lines through the boxes represent 95% confidence intervals (CI). The
centers of the boxes are situated in the point estimate (OR/RR), and the bigger boxes mean studies have relatively greater influence in the summary
estimates.
doi:10.1371/journal.pone.0034615.g002
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PLoS ONE | www.plosone.org 5 April 2012 | Volume 7 | Issue 4 | e34615for LINE-1 is located in the 59 region which is often deleted
without knowing the exact frequency; consequently the numbers
of elements used for LINE-1 measurement can be different across
samples. Phokaew et al. [57] reported that LINE-1 methylation
levels of white blood cells and normal oral epithelium were highly
variable depending on where the targeted sequence are located,
but similar pattern was observed in the same locus. This result
suggests that targeting locus for LINE-1 methylation measurement
in normal tissues should be cautiously selected, but the amount of
variation of methylation levels across samples may not be large.
Five out of 7 studies of involving LINE-1 methylation in our study
used the same target sequence for LINE-1, and they were all
referenced from Bollati et al. [58]. The summery estimates of these
studies showed little heterogeneity and showed significant
association with cancer risk. Liao et al. [45] reported global
DNA methylation levels at 4 different positions; however,
associations with cancer risk were different in each position.
Because the studies were performed at different cancer sites, it
cannot be concluded whether experimental methods were more
important than the cancer type in the association between cancer
risk and global DNA methylation using peripheral blood. How-
ever, these results suggest that the experimental methods used to
quantify global DNA methylation levels are important factors in
the association study with cancer risk.
The effects of aberrant DNA methylation of promoter regions
on cancer risk are relatively clear. However, the relationship
between global DNA hypomethylation and cancer are not
conclusive. Global DNA hypomethylation is related to early stages
of carcinogenesis [7–9], tumor progression [29], or both [59].
Global hypomethylation may function as a cause or consequence
of carcinogenesis. However, the present results could not confirm
the association. Most studies (10 out of 11 studies) had a case-
control design. The only cohort study in the meta-analysis had
small cancer incidence cases and showed inconsistent results with
different methods.
DNA hypomethylation in blood leukocytes of patients with
cancer might be caused by circulating tumor DNA [60]. However,
the effects of tumor DNA on the results of the present study seem
Figure 3. Subgroup analysis of the association between cancer risks and global DNA hypomethylation in peripheral blood
leukocytes. (A) %5-mC, (B) LINE-1, and (C) LINE-1 used same target sequence. The association between bladder cancer risk and global DNA
hypomethylation (D). R: random effects model. Summary estimates were calculated based on a fixed effects model, unless otherwise stated.
doi:10.1371/journal.pone.0034615.g003
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PLoS ONE | www.plosone.org 6 April 2012 | Volume 7 | Issue 4 | e34615to be minimal. Active and aggressive tumors release tumor DNA
but hypomethylation can be found in early stages of cancer, and
tumor DNA is detected in the plasma of cancer patients but the
methylation levels were assessed using blood leukocyte.
The limitation of this study is that a small number of
publications met the criteria for the present meta-analysis and
that these articles were mostly case-control designed studies.
Although global DNA hypomethylation in blood leukocytes was
associated with increased cancer risk in the meta-analysis, global
DNA hypomethylation may be useful as a biomarker for cancer
susceptibility but not a diagnostic tool for cancer. Because it is
difficult to decide the cut-off point of hypomethylation for a
biomarker for cancer risk, the sensitivity and specificity of global
hypomethylation regarding cancer risks could not be determined.
In summary, global DNA hypomethylation in peripheral blood
leukocytes may be considered as a biomarker for cancer risk.
However, the association with cancer risk may vary with
experimental methods, and targeted region of DNA to measure
global hypomethylation levels, and cancer type. Numerous
methods are available to measure global DNA methylation but
are limited for epidemiological studies, which require techniques
that are high-throughput, accurate, and economical. Further
investigation is needed to elucidate surrogate markers for global
DNA methylation levels and to determine whether global DNA
hypomethylation is a marker of cancer risk with large cohort
studies.
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